|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
PBMs: Merck-Medco in the Hot Seat
Author(s)Andra Brichacek
Franklin Lakes, New Jersey-Merck’s pharmacy benefit arm, Merck-Medco, is under fire for switching patients to more expensive pharmaceuticals.
Advertisement
Articles in this issue
over 24 years ago
National Crisis Supercedes Coverage Debateover 24 years ago
National Crisis Supercedes Coverage Debateover 24 years ago
A Five-Year Forecast: Clear Seas Ahead?over 24 years ago
Weak Bones, Strong Marketover 24 years ago
Approvals: Novartis’ Silver Liningover 24 years ago
Pfizer and others Pitch Inover 24 years ago
Oncology: EMEA Approval Lagsover 24 years ago
Illegal Sales in Indiaover 24 years ago
Health Plan Premiums: Pharma Takes the Blameover 24 years ago
Little Elan Becomes a Big DealAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
2
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma
3
The New Healthy Aging Imperative and What It Means for Pharma
4
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
5